Clinical trials
Phase 3 Lymphoma, Follicular trials in Israel
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Active, not recruiting | 6 |
| Terminated | 4 |
| Recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Gilead Sciences | 3 |
| Regeneron Pharmaceuticals | 3 |
| European Organisation for Research and Treatment of Cancer - EORTC | 2 |
| Genmab | 2 |
| German High-Grade Non-Hodgkin's Lymphoma Study Group | 2 |
| Janssen Research & Development, LLC | 2 |
| BeOne Medicines | 1 |
| EBMT Solid Tumors Working Party | 1 |
| Incyte Corporation | 1 |
| Pfizer | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, Follicular | 22 |
| Lymphoma, B-Cell, Marginal Zone | 10 |
| Lymphoma | 7 |
| Lymphoma, Non-Hodgkin | 7 |
| Lymphoma, Large B-Cell, Diffuse | 6 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 |
| Lymphoma, Mantle-Cell | 5 |
| Waldenstrom Macroglobulinemia | 5 |
| Burkitt Lymphoma | 4 |
| Lymphoma, Large-Cell, Immunoblastic | 4 |
Trials
Showing 1 to 22 of 22. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.